【摘要】 目的研究阿奇霉素联合乙酰半胱氨酸对慢性阻塞性肺疾病(COPD)稳定期患者肺功能及炎症因子水平的影响。方法将2017年7月至2019年6月我院收治的90例COPD稳定期患者按照随机数字法分为对照组和联合组,各45例。对照组在常规治疗基础上给予阿奇霉素,联合组在对照组基础上给予乙酰半胱氨酸。比较两组的肺功能指标、炎症指标及不良反应发生情况。结果治疗后,两组FEV1、FEV1%pred和FEV1/FVC均明显升高,TNF-α、IL-10和GRO-α水平均明显降低,且联合组优于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论阿奇霉素联合乙酰半胱氨酸能够有效减轻COPD稳定期患者的炎症反应,改善其肺功能,安全性好。更多还原

【Abstract】 Objective To study the influences of azithromycin combined with acetylcysteine on pulmonary function and the level of inflammatory factors in chronic obstructive pulmonary disease(COPD) patients in stable stage.Methods Ninety patients with COPD in stable stage enrolled in our hospital from July 2017 to June 2019 were divided into control group and combined group according to the random number method,with 45 cases in each group.The control group was given azithromycin on the basis of conventional treatment,and the combined group was given acetylcysteine on the basis of the control group.Pulmonary function,inflammation indexes and adverse reactions were compared between the two groups.Results After treatment,FEV1,FEV1%pred and FEV1/FVC of the two groups increased significantly,the levels of TNF-α,IL-10 and GRO-α reduced significantly,and those of the combined group were better than the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Azithromycin combined with acetylcysteine can effectively reduce the inflammatory response of COPD patients in stable stage,and improve the patients’ lung function,with good safety.更多还原